Family planning visits could double as HIV prevention for young women

NCT ID NCT04666792

Completed Prevention Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at whether offering HIV prevention services, including PrEP medication, in family planning clinics helps more young women get tested for HIV and start PrEP. Over 25,000 sexually active, HIV-negative young women in Kenya took part. The goal was to see if integrating these services into routine care is practical and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PrEP (emtricitabine/tenofovir disoproxil fumarate)
What this could lead to: If successful, this approach could make it easier for young women to access HIV prevention during routine family planning visits, potentially reducing new HIV infections.
What could go wrong: This is an implementation study, not a test of PrEP's effectiveness. Results may depend on clinic resources and patient adherence, and may not apply to other settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTRACEPTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sexually transmitted disease HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTRACEPTION HIV INFECTIONS STI

Contacts and locations

Locations

Kenyatta National Hospital

Kisumu, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.